Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

Two Labs Blog

Failure to Launch: Five key reasons that biosimilars have failed to gain traction in the US market

Posted by Jessica Krauser on November 1, 2018
Find me on:

Although biosimilars have taken off in Europe, they have yet to gain significant traction in the United States. More than thirty biosimilars have been approved and twenty-six are marketed in Europe. In the US, there are only eleven biosimilars approved with only five marketed: Zarxio, Fulphila, Retacrit, Renflexis, and Inflectra.

Read the full report by downloading this paper.

Download White Paper